The Bundeskartellamt has given the green light for the participation of full-line pharmaceutical wholesalers in the “VCI Emergency Platform for Vaccination Equipment.” The platform was launched with the Bundeskartellamt’s approval to better coordinate the supply of vaccination equipment (syringes, cannulas, and NaCI solution).
According to federal government plans, the pharmaceutical wholesale industry is to take control, together with the pharmacies, of the supply of the COVID-19 vaccine to physicians from the second quarter of 2021. This will also involve the provision of complete sets of vaccine and the necessary vaccination equipment.
Andreas Mundt, President of the Bundeskartellamt, said, “As the availability of vaccines will hopefully increase soon, their distribution will have to be optimised. This calls for close cooperation between different companies and public bodies. We already sent out a swift and unbureaucratic signal in February for the cooperation within the context of the ‘Emergency Platform for Vaccination Equipment.’ In our view it is therefore appropriate to open up the platform to the pharmaceutical wholesale industry. This sector can play an important role in distributing the vaccine and putting together vaccine sets. All in all it is assumed that the supply situation will improve with the help of the platform and the involvement of all the relevant market players. The platform’s duration is to be limited to the pandemic emergency situation.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Files Suit Against Liquor Giant Southern Glazer’s Over Discount Disparities
Dec 12, 2024 by
CPI
Racing Rivals Accuse NASCAR of Retaliation in High-Stakes Antitrust Battle
Dec 12, 2024 by
CPI
Samsung Challenges Indian Antitrust Investigation, Calls Raid “Unlawful”
Dec 12, 2024 by
CPI
European Sites Criticize Google’s Compliance Efforts with DMA
Dec 12, 2024 by
CPI
Banco BPM Overcomes Regulatory Hurdle in $1.7 Billion Bid
Dec 12, 2024 by
CPI
Antitrust Mix by CPI
Coopetition in The Pharma Industry: Challenges for Antitrust
Dec 12, 2024 by
Juan Delgado & Lourdes Sosa
Symmetry and the Sixth Force: The Essential Role of Complements
Dec 12, 2024 by
Adam Brandenburger & Barry Nalebuff
ESG Collaborations in Light of European Antitrust Policy and Enforcement Trends
Dec 12, 2024 by
Christian Ritz, Julia Gingelmaier & Kyra Harmes
Antitrust Chronicle® – Co-opetition
Dec 11, 2024 by
CPI
Antitrust Chronicle® – Moats & Entrenchment
Nov 29, 2024 by
CPI